Clinical Trials Logo

Hematopoietic/Lymphoid Cancer clinical trials

View clinical trials related to Hematopoietic/Lymphoid Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04138875 Withdrawn - Clinical trials for Hematopoietic/Lymphoid Cancer

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Start date: January 2022
Phase: Phase 2
Study type: Interventional

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction. The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).

NCT ID: NCT01988701 Withdrawn - Clinical trials for Graft Versus Host Disease

Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease

Start date: February 2015
Phase: N/A
Study type: Observational

This research trial studies lymphocyte profiles and activation status in patients with graft-versus-host disease. Studying samples of blood in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to graft-versus-host disease.

NCT ID: NCT01660347 Withdrawn - Anemia Clinical Trials

Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant

Start date: August 2012
Phase: N/A
Study type: Interventional

This clinical trial studies how well donor stem cell boost works in treating patients with low blood cells after donor stem cell transplant. Donor stem cell boost may increase low blood cell counts caused by hematologic cancer or its treatment.

NCT ID: NCT01620229 Withdrawn - Clinical trials for Hematopoietic/Lymphoid Cancer

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best way to give brentuximab vedotin and to see how well it works after donor stem cell transplant in treating patients with hematologic malignancies. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Monoclonal antibodies may kill cancer cells that are left after donor stem cell transplant.

NCT ID: NCT00899808 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer

Start date: May 2006
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.

NCT ID: NCT00737191 Withdrawn - Pain Clinical Trials

Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

Start date: August 2008
Phase: N/A
Study type: Interventional

RATIONALE: Opioids lessen pain caused by cancer. It is not yet known whether opioids are more effective when given together with or without olanzapine in treating cancer pain. PURPOSE: This randomized clinical trial is studying opioids to see how well they work when given together with or without olanzapine in treating patients with moderate to severe cancer pain.